Immune-based Therapies
Dual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade-Long Idiopathic Pericarditis: A Case Report
Respirology Case Reports 2024 May 26 [Link] Beatriz Grau Mirete, Paula Rodriguez Paya, Mariano Martinez Marin, Asia Ferrández Arias, Miguel Borregón Rivilla, Antonio David Lazaro Sanchez, Pedro Morillas Blasco, Alvaro Rodriguez-Lescure, Javier David Benítez Fuentes Abstract Malignant pericardial mesothelioma (MPeM) is exceptionally rare, and its association with long-standing idiopathic pericarditis remains unreported. We present a…
Read MoreA bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023
Journal of Thoracic Cancer 2025 April 30 [Link] Sheng Chen, Ce Zhao, Ruiqi Liu, Wenjie Jiao Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor originating from the mesothelial lining of the pleural cavity. It is characterized by extensive nodular pleural thickening and has a propensity to invade the pleural adipose tissue and adjacent…
Read MoreBreaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…
Read MoreBAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives
Cancers 2025 May 6 [Link] Susana Cedres, Augusto Valdivia, Ilaria Priano, Pedro Rocha, Patricia Iranzo, Nuria Pardo, Alex Martinez-Marti, Enriqueta Felip Abstract Pleural mesothelioma (PM) is a locally aggressive tumor associated with asbestos exposure. Despite legislative efforts to regulate asbestos use, its incidence continues to rise in some parts of the world. Chemotherapy and immunotherapy…
Read MoreMolecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
International Journal of Molecular Sciences 2025 May 1 [Link] Taketo Kato, Ichidai Tanaka, Heng Huang, Shoji Okado, Yoshito Imamura, Yuji Nomata, Hirofumi Takenaka, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa Abstract Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in…
Read MorePD-1 Blockade Mitigates Surgery-Induced Immunosuppression and Increases the Efficacy of Photodynamic Therapy for Pleural Mesothelioma
Cancer Research Communications 2025 May 1 [Link] Gwendolyn M Cramer, Richard W Davis 4th, Emmanouil Papasavvas, Astero Klampatsa, Joann M Miller, Shirron Carter, Ruth Ikpe, Min Yuan, Sandy Widura, R Sonali Majumdar, Sally McNulty, Mary Putt, Andrew V Kossenkov, Luis J Montaner, Sunil Singhal, Edmund K Moon, Steven M Albelda, Keith A Cengel, Theresa M…
Read MoreEfficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Medicina 2025 March 31 [Link] Ziya Kalkan, Senar Ebinc, Murat Arcagok, Ahmet Bilici, Ozcan Yildiz, Saadettin Kilickap, Deniz Can Guven, Ali Murat Tatli, Ahmet Taner Sumbul, Nil Molinas Mandel, Akin Ozturk, Murat Bardakci, Serdar Karakaya, Muhammet Ali Kaplan Abstract Background and Objectives: This study aimed to evaluate the effectiveness of immunotherapy compared to chemotherapy across…
Read MoreTumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook
Current Treatment Options in Oncology 2025 May [Link] Giovanni Luca Ceresoli, Letizia Gianoncelli Abstract Pleural mesothelioma is an incurable cancer with unmet diagnostic and therapeutic needs. Due to its pattern of local spread, few patients are candidates for multimodality treatment and thus most patients only receive systemic therapy. Chemotherapy (pemetrexed plus platinum) was standard of…
Read MoreImmunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR
Journal of Chemotherapy 2025 April 22 [Link] Marko Skelin, Kaja Matić, Andrea Anić-Matić, Ivan Krečak, Bruna Perkov-Stipičin, Mirko Grubor Abstract Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search included 7…
Read MoreRadical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan, Elena Muraro Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure,…
Read More